title: Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
abstract: Children and adolescents with symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) of grade >/=2 (n=45) or nonerosive esophagitis (NEE) (n=45) were assessed to determine the relationship between presenting symptoms, esophagitis severity, and patient age. Overall, regurgitation/vomiting, abdominal pain, and cough were the most frequent symptoms. The prevalence and severity of anorexia/feed refusal was significantly greater in EE versus NEE children; this symptom was also significantly more prevalent in younger (1-5 years) children (both NEE and EE groups) compared to older children. Cough was significantly less severe in NEE adolescents than in younger children. Cough, anorexia/feed refusal, and regurgitation/vomiting were more severe and heartburn was less severe in EE children aged 1-5 years compared with older patients. In conclusion, GERD in children manifests differently than that in adults and symptoms vary with patient age. Symptoms were not predictive of presence or lack of mucosal damage.
authors.affiliation: Riley Hospital for Children, 702 Barnhill Dr, Room ROC 4210, Indianapolis, IN 46202, USA. sgupta@iupui.edu
authors.forename: Sandeep K
authors.initials: SK
authors.lastname: Gupta
authors.forename: Eric
authors.initials: E
authors.lastname: Hassall
authors.forename: Yi-Lin
authors.initials: YL
authors.lastname: Chiu
authors.forename: Fouad
authors.initials: F
authors.lastname: Amer
authors.forename: Melvin B
authors.initials: MB
authors.lastname: Heyman
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D015746:Abdominal Pain / Q000453:epidemiology / Q000209:etiology; D000293:Adolescent; D000855:Anorexia / Q000209:etiology; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003371:Cough / Q000453:epidemiology / Q000209:etiology; D003430:Cross-Sectional Studies; D016145:Endoscopy, Digestive System; D004941:Esophagitis / Q000503:physiopathology*; D004942:Esophagitis, Peptic / Q000145:classification / Q000150:complications*; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007223:Infant; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D012720:Severity of Illness Index; D014839:Vomiting / Q000453:epidemiology / Q000209:etiology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole